Staying on 2.5mg Mounjaro for maintenance: what the evidence says

You've finished your first pen, now what?

Picture this: you've been injecting for four weeks, the nausea wasn't as bad as you feared, and you're wondering whether it's safer to stay put rather than increase. It's a completely understandable instinct. The first Mounjaro pen is daunting, and once you find a dose that feels tolerable, pausing there feels sensible.

The reason 2.5mg exists is not therapeutic, it's a settling-in dose. At that concentration, tirzepatide activates GIP and GLP-1 receptors gently, reducing the sharp gastrointestinal side effects that a higher starting dose would bring. Most people notice very little appetite change at 2.5mg, because the dose isn't high enough to exert the hormonal effect that drives sustained weight loss.

Clinical trial data from the SURMOUNT programme, involving thousands of adults with obesity, showed average weight reductions of around 20% at the 15mg dose over 72 weeks. Those results were achieved through structured titration, participants didn't reach meaningful loss by staying at the entry level. Staying at 2.5mg long-term is a bit like leaving a prescription half-filled: the medicine is genuine, but it isn't doing the job it was licensed to do. You can read more about why 2.5mg isn't considered a maintenance dose and what the alternatives look like.

What counts as maintenance on Mounjaro, and why the number varies

Maintenance on Mounjaro means the dose at which your weight loss plateaus at an acceptable level and side effects are manageable enough to continue. That isn't the same dose for everyone. The licensed UK strengths run from 2.5mg up to 15mg, in 2.5mg increments. Titration typically moves in four-week steps, and a prescriber may choose to slow that down if side effects are troublesome or pause a step-up if circumstances change, a holiday abroad, a stomach bug, a stressful patch at work.

Some people find that 5mg produces a sustained and clinically meaningful response and their prescriber agrees that going higher isn't necessary. That's a legitimate outcome. Others need 10mg or 15mg before their appetite and weight stabilise. The licensed maintenance concept is explored further on the Mounjaro maintenance dose overview page, which covers how prescribers think about it.

What is clear from the SmPC and clinical guidance is that 2.5mg is not in the conversation for maintenance. It appears in the schedule as a four-week step only. If your prescriber has suggested staying at a low dose for a specific clinical reason (managing a particular health condition, for instance) that is a bespoke clinical decision, not the standard pathway, and it should be documented and reviewed regularly. The question of how long you stay on a maintenance dose is a separate one worth understanding too.

What happens if you stay at 2.5mg against clinical advice

In practice, most people who try to stay at 2.5mg indefinitely find that weight loss stalls quickly, often within the first four to six weeks. The appetite-suppressing effect of tirzepatide at this dose is minimal for most adults, and without a meaningful reduction in caloric intake, body weight won't shift significantly. The biological reality is that the dose needs to reach a threshold at which GIP and GLP-1 signalling reliably suppresses appetite and slows gastric emptying enough to change eating patterns.

There's also a cost consideration worth naming plainly: Mounjaro isn't inexpensive. If you're paying privately for treatment and want to understand what different doses cost across the market, the Mounjaro cost and pricing guide gives honest context. Staying at 2.5mg to save money is unlikely to give you the outcome you're paying for.

The other risk of self-managing your dose (staying put when your prescriber has recommended titrating) is that it separates you from the clinical oversight that makes treatment safe. Prescribers adjust doses based on your progress, your bloodwork where relevant, and your reported side effects. Staying at 2.5mg without flagging it to your clinical team means they're working from a false picture of where you are. If you have concerns about moving up, the right step is to raise them with your prescriber, not to quietly stay put.

Talking to your prescriber about the pace of titration

Concerns about increasing your dose are legitimate and worth voicing. Side effects from tirzepatide are real, nausea, loose stools, fatigue and reflux are among the most common, particularly around dose increases, though they usually settle within a couple of weeks. If you've had a difficult time at 2.5mg, that's important clinical information.

A prescriber may decide to extend the time at a given dose, rather than increase on the standard four-week schedule. That is different from staying at 2.5mg forever, it's a temporary pause to let your system catch up. For people considering whether 5mg could be the right maintenance level, or whether 7.5mg is where they should aim, those are questions with real clinical nuance behind them.

At nume, every repeat order is reviewed by a GPhC-registered Independent Prescriber before dispatch, a real clinician reads your update, not a queue for automated processing. If you want to discuss your titration pace, our prescribers are available seven days a week. The clinical team at nume takes that conversation seriously. If you're ready to talk through your options, check your eligibility and start a free consultation.